Date: June 03, 2026

Investment in Subsidiary

Tarsons Products Limited has completed the second tranche of equity investment amounting to EUR 552,000 (Five Hundred Fifty-Two Thousand Euros Only) in its wholly-owned subsidiary, Tarsons Life Science Pte. Ltd., Singapore, on June 03, 2026.

The Company subscribed to 184 equity shares at a nominal value of EUR 3,000 per share. This investment is part of the total approved equity infusion of EUR 3,000,000 (Three Million Euros) that was previously approved by the Board of Directors and intimated to stock exchanges on February 06, 2026.

The first tranche of EUR 300,000 was completed on April 09, 2026, involving subscription to 100 equity shares.

Purpose of Investment

The proceeds shall be utilized by the subsidiary towards:

  • Repayment of bank loan in Singapore
  • Payment of interest on bank loan
  • Meeting general corporate purposes
  • Operational requirements
  • Other financial obligations

Related Party Transaction Details

The transaction falls within related party transaction as Tarsons Life Science Pte. Ltd. is a wholly-owned subsidiary. The transaction is conducted at arm's length basis.

Promoter/promoter group companies have no interest in the target entity other than through their shareholding in Tarsons Products Limited.

Directors Mr. Aryan Sehgal, Mr. Sanjive Sehgal, and Mr. Subramanian Arun Kumar hold directorships in both the Company and the Target Entity.

Subsidiary Information

Tarsons Life Science Pte. Ltd. is engaged in Non-Operating Financial Holding Companies and is classified as a Special Purpose Vehicle.

Incorporation Date: November 10, 2023

Country of Presence: Singapore

Financial Performance:

  • FY 2023-24: Turnover Nil
  • FY 2024-25: Turnover Nil
  • FY 2025-26: Turnover Nil

Transaction Details

Consideration Type: Cash Consideration

Total Cost: EUR 552,000 for 184 shares

Price per Share: EUR 3,000

Ownership Impact: No change in ownership percentage - remains wholly-owned subsidiary

Governmental Approvals: Not Applicable

Completion Status: Completed

Company Representatives

Santosh Kumar Agarwal, CFO, Company Secretary and Compliance Officer (ICSI Membership No. A44836) signed the disclosure.